Astrana Health (ASTH) Expected to Post Earnings on Thursday

Astrana Health (NASDAQ:ASTH) is anticipated to post its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of $0.3362 per share and revenue of $985.6860 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 5:30 PM ET.

Astrana Health (NASDAQ:ASTH) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.74 EPS for the quarter, beating analysts’ consensus estimates of $0.29 by $0.45. The company had revenue of $965.10 million during the quarter, compared to the consensus estimate of $949.21 million. Astrana Health had a net margin of 0.86% and a return on equity of 9.22%. The company’s quarterly revenue was up 55.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.42 EPS. On average, analysts expect Astrana Health to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Astrana Health Stock Down 1.8%

Astrana Health stock opened at $35.27 on Tuesday. The company has a debt-to-equity ratio of 1.20, a current ratio of 1.35 and a quick ratio of 1.35. The company’s 50-day moving average is $41.59 and its 200-day moving average is $32.26. The firm has a market capitalization of $1.97 billion, a PE ratio of 57.81 and a beta of 0.87. Astrana Health has a fifty-two week low of $18.08 and a fifty-two week high of $51.60.

Analyst Upgrades and Downgrades

ASTH has been the subject of a number of research analyst reports. Truist Financial lifted their price target on Astrana Health from $38.00 to $47.00 and gave the stock a “buy” rating in a report on Thursday, May 14th. BTIG Research increased their price objective on shares of Astrana Health from $50.00 to $65.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. Barclays upgraded Astrana Health from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $37.00 to $50.00 in a research note on Tuesday, May 26th. Needham & Company LLC boosted their price objective on shares of Astrana Health from $30.00 to $41.00 and gave the company a “buy” rating in a report on Friday, May 8th. Finally, Weiss Ratings raised Astrana Health from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 1st. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $47.86.

Institutional Investors Weigh In On Astrana Health

A number of institutional investors have recently added to or reduced their stakes in the business. State Street Corp raised its stake in shares of Astrana Health by 6.2% during the fourth quarter. State Street Corp now owns 1,675,516 shares of the company’s stock valued at $41,570,000 after acquiring an additional 98,064 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Astrana Health by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 1,028,168 shares of the company’s stock worth $25,513,000 after purchasing an additional 12,212 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Astrana Health by 418.3% in the fourth quarter. Wellington Management Group LLP now owns 738,853 shares of the company’s stock worth $18,331,000 after purchasing an additional 596,293 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its holdings in Astrana Health by 19.2% in the third quarter. Jacobs Levy Equity Management Inc. now owns 500,527 shares of the company’s stock valued at $14,190,000 after purchasing an additional 80,465 shares during the period. Finally, Ameriprise Financial Inc. increased its holdings in Astrana Health by 231.0% in the third quarter. Ameriprise Financial Inc. now owns 442,314 shares of the company’s stock valued at $12,540,000 after purchasing an additional 308,665 shares during the period. 52.77% of the stock is owned by institutional investors.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.